<DOC>
	<DOCNO>NCT00142337</DOCNO>
	<brief_summary>The purpose study determine whether provide zidovudine ( ZDV ) didanosine ( ddI ) labor one month postpartum reduce selection nevirapine ( NVP ) resistance mutation postpartum woman receive single dose nevirapine labor standard ZDV prophylaxis prevention mother child transmission HIV .</brief_summary>
	<brief_title>One Month Dual Antiretroviral Prophylaxis Prevent Resistance Mutations Mothers Exposed Single Dose Nevirapine</brief_title>
	<detailed_description>A single nevirapine dose mother , without dose child , addition oral ZDV prophylaxis start 28 week gestation proven highly effective reduce mother-to-child HIV transmission ( PMTCT ) . However , post exposure nevirapine resistance mutation observe mother 's viral population . These mutation detectable early exposure tend disappear time . Nevertheless , may associate decrease efficacy non-nucleoside reverse transcriptase inhibitor ( NNRTI ) contain regimen subsequently give woman health . Therefore , need research prevent selection resistance first place overcome resistance subsequent treatment infect mother infant . Nevirapine plasma level IC50 detect woman expose single 200 mg dose nevirapine significant number woman third week postpartum . We hypothesize give ZDV+ddI woman expose nevirapine one month soon possible exposure may prevent selection nevirapine resistance mutation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Meet preentry criterion ; Consent participate follow duration study ; Present follow laboratory value within 14 day prior inclusion : Hemoglobin &gt; 8.0 mg/dl Absolute neutrophil count &gt; 1000 cells/mm3 Platelets &gt; 100,000 cells/mm3 Serum creatinine &lt; 1.5 mg/dl ( woman serum creatinine &gt; 1.5 mg/dl must measure eighthour urine creatinine clearance &gt; 70 ml/min ) SGPT le 10 time upper limit normal Amylase le 150/L IU ( upper limit may change slightly depend normal range hospital laboratory ) . Evidence preexist fetal anomaly incompatible life ; Known hypersensitivity benzodiazepine NVP ; Receipt antiretroviral agent ZDV ; Receipt nonallowed concomitant treatment contraindication ddI Concurrent participation another clinical trial ; Women CD4 count &lt; 200/ÂµL history oral candidiasis receive pneumocystis carinii pneumonia ( PCP ) prophylaxis Any contraindicate drug ZDV+ddI treatment mother well child ( Contraindicated drug gancyclovir , isoniazid , linezolid , ethambutol , rifabutin , cidofovir allow ZDV ddI treatment delivery order prevent pharmacological interaction overlap toxicity . )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>zidovudine</keyword>
	<keyword>didanosine</keyword>
	<keyword>Prevention mother child transmission HIV</keyword>
	<keyword>nevirapine</keyword>
	<keyword>Thailand</keyword>
	<keyword>Resistance</keyword>
	<keyword>HIV</keyword>
	<keyword>Postpartum period</keyword>
</DOC>